Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b/2a dose-escalation study of iberdomide combinations in newly diagnosed multiple myeloma
MOH_2022-11-05_012161Phase 2Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum tolerated dose, Safety and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-11-05_012161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-05_012161.